RAPT Therapeutics RAPT 深 滬
等待開盤 07-26 09:30:00 美东时间
13.31
+0.660
+5.22%
華盛通- 最 高13.4589
- 今 開12.65
- 成交量 6.63万股
- 最 低 12.1412
- 昨 收 12.65
- 總市值 2.20亿
- 52周最高 26.56
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.6656
- 委 比 -97.82%
- 總股本 1653.61万
- 歷史最高 409.68
- 量 比 0.66
- 振 幅 10.42%
- 歷史最低 5.6656
- 每 手 1
- 風險率 4.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 丰业银行上调Meta目标价从525美元升至675美元；恩智浦获"超配"评级，目标价从190美元升至220美元
今日重点评级关注：瑞杰金融：维持Antero Resources Corp."强烈买入"评级，目标价从57美元升至58美元；美银证券：维持和黄医药"买入"评级，目标价从27美元升至28美元
07-23 09:42
LifeSci Capital Initiates Coverage On RAPT Therapeutics with Outperform Rating, Announces Price Target of $31
LifeSci Capital initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Outperform rating and announces Price Target of $31.
07-23 05:08
HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $27
HC Wainwright & Co. analyst Emily Bodnar maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price target from $6 to $27.
07-10 18:25
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
RAPT Therapeutics announced the addition of Scott Braunstein, M.D., to its Audit Committee and Ashley Dombkowski, Ph.D., to its Nominating and Corporate Governance Committee. Both bring extensive industry experience. RAPT’s lead product, RPT904, a novel monoclonal antibody targeting free IgE, is completing Phase 2 trials in chronic spontaneous urticaria and asthma, with plans for a Phase 2 study in food allergy later this year. The company aims t...
06-23 12:00
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
RAPT Therapeutics, Inc. announced a 1-for-8 reverse stock split effective June 16, 2025. The company's common stock will continue trading on the Nasdaq Global Market under the same symbol "RAPT" with a new CUSIP number. The reverse split will reduce outstanding shares from approximately 132.3 million to 16.5 million, while increasing the number of authorized shares available for future issuance. Adjustments will also be made to pre-funded warrant...
06-13 13:00
RAPT Therapeutics Announces Development Plans for RPT904
RAPT Therapeutics ( ($RAPT) ) has shared an update. RAPT Therapeutics announced...
06-10 04:50
RAPT Therapeutics to Participate in Upcoming Investor Conferences
RAPT Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on treating inflammatory and immunological diseases, announced that its management team will participate in two investor conferences in June: a fireside chat at Goldman Sachs' Global Healthcare Conference on June 10 and investor one-on-one meetings at the UBS Spring Biotech Conference on June 24. Visit their website for details on accessing the Goldman Sachs event.
06-04 20:05
RAPT Therapeutics Faces Nasdaq Delisting Notice
RAPT Therapeutics ( ($RAPT) ) has issued an update. On May 21, 2025, RAPT Thera...
05-29 04:29
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers SCWorx (NASDAQ:WORX) shares rose 60.0% to $0.64 during Tuesday's regul...
05-28 01:05
美股大行评级 | 高盛上调微软目标价从480美元至550美元，Snowflake获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132593314765758464.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持IDEAYA Biosciences(IDYA)"超配"评级，目标价从63美元升至66美元</p> <p>• Needham：上调Inogen(INGN)评级至"买入"，目标价12美元</p> <p>• E
05-23 11:19
